Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2015 (2015), Article ID 623092, 8 pages
http://dx.doi.org/10.1155/2015/623092
Case Report

Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson’s Syndrome: A Case Report and Review of the Literature

1Department of Endocrinology, Medical University of Lublin, Lublin, Poland
2Department of Neurosurgery, Military Medical Institute, Warsaw, Poland
3Department of Pathology, M. Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland

Received 23 April 2015; Accepted 15 June 2015

Academic Editor: Carlo Capella

Copyright © 2015 Maria Kurowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Patel, J. A. Eloy, and J. K. Liu, “Nelson's syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies,” Neurosurgical Focus, vol. 38, no. 2, article E14, 2015. View at Publisher · View at Google Scholar
  2. T. M. Barber, E. Adams, and J. A. Wass, “Nelson syndrome: definition and management,” in Handbook of Clinical Neurology, vol. 124 of Clinical Neuroendocrinology, chapter 22, pp. 327–337, Elsevier, New York, NY, USA, 2014. View at Publisher · View at Google Scholar
  3. C. Pozza, C. Graziadio, E. Giannetta, A. Lenzi, and A. M. Isidori, “Management strategies for aggressive Cushing's syndrome: from macroadenomas to ectopics,” Journal of Oncology, vol. 2012, Article ID 685213, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. F. E. Wondisford, “A new medical therapy for Cushing disease?” The Journal of Clinical Investigation, vol. 121, no. 12, pp. 4621–4623, 2011. View at Publisher · View at Google Scholar
  5. O. Moshkin, L. V. Syro, B. W. Scheithauer et al., “Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy,” Hormones, vol. 10, no. 2, pp. 162–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. D. Ortiz, L. V. Syro, B. W. Scheithauer et al., “Temozolomide in aggressive pituitary adenomas and carcinomas,” Clinics, vol. 67, supplement 1, pp. 119–123, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. S. Zuhur and Y. Altuntaş, “The role of temozolomide in the treatment of aggressive pituitary adenomas and pituitary carcinomas,” The Medical Bulletin of Şişli Etfal Hospital, vol. 46, no. 3, pp. 157–164, 2012. View at Google Scholar
  8. T. H. Dillard, S. H. Gultekin, J. B. Delashaw Jr., C. G. Yedinak, E. A. Neuwelt, and M. Fleseriu, “Temozolomide for corticotroph pituitary adenomas refractory to standard therapy,” Pituitary, vol. 14, no. 1, pp. 80–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Raverot, N. Sturm, F. de Fraipont et al., “Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4592–4599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. L. V. Syro, L. D. Ortiz, B. W. Scheithauer et al., “Treatment of pituitary neoplasms with temozolomide: a review,” Cancer, vol. 117, no. 3, pp. 454–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Losa, E. Mazza, M. R. Terreni et al., “Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases,” European Journal of Endocrinology, vol. 163, no. 6, pp. 843–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. L. V. Syro, H. Uribe, L. C. Penagos et al., “Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm,” Clinical Endocrinology, vol. 65, no. 4, pp. 552–553, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. C. E. Fadul, A. L. Kominsky, L. P. Meyer et al., “Long-term response of pituitary carcinoma to temozolomide. Report of two cases,” Journal of Neurosurgery, vol. 105, no. 4, pp. 621–626, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. V. J. Moyes, G. Alusi, H. I. Sabin et al., “Treatment of Nelson's syndrome with temozolomide,” European Journal of Endocrinology, vol. 160, no. 1, pp. 115–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Takeshita, N. Inoshita, M. Taguchi et al., “High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease,” European Journal of Endocrinology, vol. 161, no. 4, pp. 553–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Mohammed, K. Kovacs, W. Mason, H. Smyth, and M. D. Cusimano, “Use of temozolomide in aggressive pituitary tumors: case report,” Neurosurgery, vol. 64, no. 4, pp. E773–E774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Jouanneau, A. Wierinckx, F. Ducray et al., “New targeted therapies in pituitary carcinoma resistant to temozolomide,” Pituitary, vol. 15, no. 1, pp. 37–43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. de Bruin, A. M. Pereira, R. A. Feelders et al., “Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 4, pp. 1118–1124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. de Bruin, R. A. Feelders, S. W. J. Lamberts, and L. J. Hofland, “Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome,” Reviews in Endocrine and Metabolic Disorders, vol. 10, no. 2, pp. 91–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Zada, W. W. Woodmansee, S. Ramkissoon, J. Amadio, V. Nose, and E. R. Laws Jr., “Atypical pituitary adenomas: incidence, clinical characteristics, and implications,” Journal of Neurosurgery, vol. 114, no. 2, pp. 336–344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Raverot, F. Castinetti, E. Jouanneau et al., “Pituitary carcinomas and aggressive pituitary tumours: Merits and pitfalls of temozolomide treatment,” Clinical Endocrinology, vol. 76, no. 6, pp. 769–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Bengtsson, H. D. Schrøder, M. Andersen et al., “Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 4, pp. 1689–1698, 2015. View at Publisher · View at Google Scholar
  23. O. Mete, S. Ezzat, and S. L. Asa, “Biomarkers of aggressive pituitary adenomas,” Journal of Molecular Endocrinology, vol. 49, no. 2, pp. R69–R78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. S. L. Asa, “Practical pituitary pathology: what does the pathologist need to know?” Archives of Pathology and Laboratory Medicine, vol. 132, no. 8, pp. 1231–1240, 2008. View at Google Scholar · View at Scopus
  25. P. Witek, G. Zieliński, M. Maksymowicz, and G. Kamiński, “Cushing's disease—assessing the efficacy of transsphenoidal surgery,” Endokrynologia Polska, vol. 63, no. 5, pp. 398–403, 2012. View at Google Scholar · View at Scopus
  26. C. G. Patil, D. M. Prevedello, S. P. Lad et al., “Late recurrences of Cushing's disease after initial successful transsphenoidal surgery,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 2, pp. 358–362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. I. McCormack, J. A. Wass, and A. B. Grossman, “Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status,” European Journal of Clinical Investigation, vol. 41, no. 10, pp. 1133–1148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. M. Bush, J. A. Longtine, T. Cunningham et al., “Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 11, pp. E280–E290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Curtò, M. L. Torre, F. Ferraù et al., “Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease—report of a case and literature review,” TheScientificWorldJOURNAL, vol. 10, pp. 2132–2138, 2010. View at Publisher · View at Google Scholar
  30. A. K. Annamalai, A. F. Dean, N. Kandasamy et al., “Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature,” Pituitary, vol. 15, no. 3, pp. 276–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. M. S. Thearle, P. U. Freda, J. N. Bruce, S. R. Isaacson, Y. Lee, and R. L. Fine, “Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor,” Pituitary, vol. 14, no. 4, pp. 418–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. B. E. Zacharia, A. P. Gulati, J. N. Bruce et al., “High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing's disease from capecitabine and temozolomide (CAPTEM): a case series,” Neurosurgery, vol. 74, no. 4, pp. E447–E455, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. L. D. Ortiz, L. V. Syro, B. W. Scheithauer et al., “Anti-VEGF therapy in pituitary carcinoma,” Pituitary, vol. 15, no. 3, pp. 445–449, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Wang, J. Li, M. Tohti et al., “The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy,” Journal of Experimental & Clinical Cancer Research, vol. 33, article 56, 2014. View at Publisher · View at Google Scholar